aphranel® Showcases Chinese Innovation in Regenerative Aesthetics at IMCAS China 2026
In September 2026, aphranel® participated in IMCAS China 2026 in Shanghai, showcasing advances in China-developed calcium hydroxylapatite (CaHA) filler technology and related scientific research. Through its exhibition booth and a dedicated scientific symposium, aphranel® engaged with international experts and industry professionals in discussions on material science, clinical applications, and injection strategies.
The congress marked an important opportunity for aphranel® to strengthen international academic exchange following its European Union Medical Device Regulation (EU MDR) certification. Through scientific presentations and clinical discussions, the brand continued to connect Chinese innovation in regenerative aesthetics with the global medical community.
Brand Showcase and Scientific Symposium
During the congress, aphranel® presented its product technologies, research developments, and EU MDR certification at its exhibition booth on the second floor. A dedicated scientific symposium was also held on the third floor, providing a platform for in-depth discussions on clinical applications and scientific innovation.
As aphranel®'s first scientific symposium following its EU MDR certification, the session focused on CaHA-based regenerative filler technology, exploring material science, regenerative mechanisms, international clinical applications, and injection strategies developed through Chinese clinical experience. The symposium complemented the congress's broader scientific programme with focused perspectives on CaHA innovation.
Three International and Chinese Experts Share Scientific and Clinical Insights
The symposium featured Dr. Shijia Wang, Dr. Zoya Evsyukova, and Dr. Yongshu Wang, who delivered presentations entirely in English. Their sessions explored CaHA filler technology from three complementary perspectives: fundamental scientific research, international clinical applications, and clinical practices in China.
Scientific Perspectives: Material Structure and Regenerative Mechanisms
Dr. Shijia Wang presented “Understanding the Science and Clinical Value of Through-Hole Calcium Hydroxylapatite Microsphere Dermal Fillers.”
Drawing on expertise in immunology, regenerative medicine, and aging research, Dr. Wang examined the structural characteristics of through-hole CaHA microspheres and discussed their interactions with the immune microenvironment, tissue repair, and regenerative processes.
Supported by scientific data and comparative research, the presentation offered insights into the relationship between biomaterial design, biological responses, and potential clinical applications.
International Perspectives: Exploring Combination Strategies in Regenerative Aesthetics
Dr. Zoya Evsyukova presented “Clinical Applications of an Innovative Chinese-Developed CaHA Filler: Combination Strategies with aphranel® MagiCCrystal in Regenerative Aesthetics.”
Drawing on international clinical experience and case studies, Dr. Evsyukova explored the application of aphranel® in combination treatment approaches for regenerative aesthetics.
Her presentation discussed treatment strategies for different clinical needs, offering insights into international practices while encouraging further exchange between Chinese biomaterial innovation and global clinical experience.
Chinese Clinical Perspectives: Scientific Understanding and Injection Strategies
Dr. Yongshu Wang, a nationally certified aphranel® Train-the-Trainer (TTT) instructor, presented “EU MDR-Certified CaHA Dermal Filler aphranel® MagiCCrystal: Scientific Insights and Injection Strategies from Chinese Clinical Experience.”
Focusing on the facial characteristics and individualized aesthetic needs of Chinese patients, Dr. Wang shared clinical perspectives on product science, injection strategies, and procedural considerations.
The presentation explored how the material properties of CaHA fillers can be considered alongside patient-specific clinical objectives, providing practical perspectives for professional discussion and treatment planning.
Connecting with the Global Aesthetic Medicine Community
Throughout IMCAS China 2026, the aphranel® booth welcomed physicians, industry professionals, and potential partners from different countries and regions.
Visitors engaged with the brand team on topics including CaHA material characteristics, product development, international regulatory certifications, and clinical applications.
By combining an exhibition presence with a dedicated scientific symposium, aphranel® provided opportunities for attendees to explore its technologies from both scientific and clinical perspectives. These interactions also offered valuable insights into international market needs and opportunities for future professional collaboration.
Advancing Scientific Innovation and International Academic Exchange
aphranel®'s participation in IMCAS China 2026 represents another step in its commitment to international scientific exchange and the advancement of regenerative aesthetic medicine.
From biomaterial research to clinical practice, the brand continues to share developments in Chinese-originated CaHA technology through open dialogue with medical professionals worldwide.
Looking ahead, aphranel® will continue to strengthen collaborations with international experts and medical institutions, connecting scientific research with evolving clinical needs while further developing its product innovation and medical education initiatives.
Through ongoing research, professional exchange, and evidence-based clinical development, aphranel® aims to contribute to the responsible and standardized advancement of regenerative aesthetics worldwide.
